What you need to know about flexible vaccines in light of RFK claims

The US Secretary of Health claimed that the Merseuled Rana vaccines are ineffective against respiratory diseases, with an announcement that it reduces half a billion dollars from financing the development of a flexible vaccine. But this contradicts our scientific evidence, which shows that many flexible vaccines are working as well – or better than – other vaccine types. Here is what you need to know to evaluate these claims.

In announcing the discounts, head of the US Department of Health and Humanitarian Services, Robert Kennedy Junior, Claim “These vaccines fail to protect effectively from upper respiratory infections such as Covid and influenza.” Kennedy said the agency will turn funding “towards safer and broader vaccine platforms that are still effective even with the transformation of viruses.”

There is now a wide range of types of vaccines: living viruses, killed viruses, genetically engineering viral shells, individual viral proteins and MRNAS coding of viral proteins. The effectiveness of all these types of vaccines is often related to the nature of the virus targeted from the vaccine itself.

For example, the MMR vaccine can be 100 percent effective in preventing measles outbreak if more than 90 percent of the population is vaccinated. But measles virus is an easy goal because it does not change much and takes a complex path in the depth of the body, which means that there are many opportunities for the immune system to object before people develop symptoms or become physicians.

In contrast, the respiratory viruses that cause colds and affect cells lined on the nose and throat. It is difficult to generate high levels of effective antibodies in these membranes, so it is very difficult to prevent infections and transport them forward from measles.

In addition, the cold, influenza and Covid-19 viruses are constantly turning, and there is a strong evolutionary choice for any mutations that help avoid immune protection resulting from infections or vaccines. For this reason, there is no influenza vaccine or Covid-19 of any kind that provides the same lifetime protection as the measles component in the MMR vaccine. But they are flexible to work relatively well.

For example, some Covid-19 vaccines were more than 90 percent effective against symptoms, with higher protection against severe diseases. For comparison, the effectiveness of non -flexible vaccines used to protect from annual influenza ranges from 20 to 60 percent. In a modern experience, a joint flexible vaccine Excellence in the performance of unlawful influenza vaccines In people over 50 years of age – those who need protection.

So Kennedy’s claim that there is no effectiveness is nonsense. This does not mean that flexible vaccines are always better than other types. But the new vaccines must outperform the most elderly performance in experiments – flexible footage will not be approved if they are not better.

Kennedy also claims that other types of vaccines are likely to remain effective with virus modification. This appears to be a sign of developing “global vaccines” – one effective vaccine against all influenza viruses, or arid that works against all Coron viruses. The idea is to target the outer parts of the unchanged viruses. But it is difficult to do this because viruses tend to hide their parts that do not change under the parts that change.

The efforts made to develop effective global vaccines have failed so far, despite decades of efforts, and therefore the focus on a lot of funding on them may be a mistake. What’s more, a flexible technology can have already been used to create an experimental global vaccines. So the second part of Kennedy’s statement is also nonsense.

Finally, not another, the event is not everything. Safety, cost and speed of vaccine development is also very important. Here is a flexible technique that has some huge advantages. It is safer than vaccines that consist of actual viruses, cheaper than vaccines that consist of one viral protein and can be developed much faster than any of the two types-which is important with fast respiratory viruses, especially in the epidemic.

In addition, technology can be used in flexible vaccines on a broader scale to develop a large group of other treatments. The financing discounts announced by Kennedy on the basis of his wrong demands can slow down development by deterring companies from investing in this approach.

Topics: